

Rebecca L Jensen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7723949/publications.pdf>

Version: 2024-02-01

11
papers

1,079
citations

932766

10
h-index

1372195

10
g-index

11
all docs

11
docs citations

11
times ranked

2419
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK. <i>Lancet Respiratory Medicine</i> , 2021, 9, 699-711.	5.2	122
2	Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study. <i>Lancet Respiratory Medicine</i> , 2021, 9, 349-359.	5.2	161
3	Importance of patient bed pathways and length of stay differences in predicting COVID-19 hospital bed occupancy in England. <i>BMC Health Services Research</i> , 2021, 21, 566.	0.9	22
4	Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK. <i>Lancet Respiratory Medicine</i> , 2021, 9, 773-785.	5.2	78
5	Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study. <i>Lancet</i> , 2021, 398, 223-237.	6.3	110
6	Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study. <i>Lancet Rheumatology</i> , 2021, 3, e498-e506.	2.2	58
7	Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. <i>Lancet Microbe</i> , 2021, 2, e354-e365.	3.4	216
8	A prenylated dsRNA sensor protects against severe COVID-19. <i>Science</i> , 2021, 374, eabj3624.	6.0	124
9	Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 1656-1665.	2.5	171
10	Safety perspectives on presently considered drugs for the treatment of COVID-19. <i>British Journal of Pharmacology</i> , 2020, 177, 4353-4374.	2.7	17
11	The mitochondrial paradox. <i>ELife</i> , 2020, 9, .	2.8	0